GNUbiome FI, a breakthrough in animal health. GNUbiome FI is an innovative Functional Ingredient derived from a natural source of AMO biosimilars* which has been clinically tested to be safe and efficacious, helping to form, maintain and improve the microbiome of cats and dogs.
GNUbiome was developed to serve animal healthcare, pet supplement and pet food manufacturers. It can be easily applied to your brands to drive new growth opportunities in the rapidly emerging microbiome health market.
GNUbiome FI is a fine off-white powder which can be added to dry or wet pet food or served as a supplement upon feeding. The product is highly stable and compatible with extrusion manufacturing processes. It is sold in 25 kilo desiccant plastic bags with currently available 700 metric tons of annual capacity.
GNUbiome FI is approved for sale in the EU, the UK and Switzerland and Gnubiotics has recently filed the GNUbiome FI dossier for FDA GRAS status approval, anticipated in mid 2022.
Interested manufacturers are kindly requested to contact Gnubiotics for more information.
* In the form of natural and diverse active glycans as glycopeptides, biosimilar in structure and functionality to the Animal Milk Oligosaccharides (AMO) found in cats and dogs’ milk.
Benefits
Adding GNUbiome FI to your formulations will bring your company’s portfolio of gastrointestinal products to a new level of efficacy and market position.
Clinical studies have shown that GNUbiome FI:
- Supports immune protection.
- Improves digestive health.
- Increases overall microbiome markers of health.
These benefits help maintain a vibrant, active and healthy pet.
Formats
GNUbiome FI is a dry, off white powder composed of AMO biosimilars.
It can easily be added to dry or wet cat and dog food. It can also be formulated into a supplement, added to a treat or included in a liquid.
If you are interested to learn more about GNUbiome FI and how it can help your company, contact us.
The science behind GNUbiome FI
GNUbiome FI is supported by scientific evidence. Discover our studies and clinical results in the publications below.
DEMONSTRATION OF SAFETY, TOLERABILITY AND UTILITY OF AMO BIOSIMILARS IN DOGS.
Evaluation of a novel animal milk oligosaccharide biosimilar: Macronutrient digestibility and gastrointestinal tolerance, fecal metabolites, and fecal microbiota of healthy adult dogs and in vitro genotoxicity assays , Anne H Lee, Sara Vidal, Patrícia M Oba, Romain Wyss, Yong Miao, Yemi Adesokan, Kelly S Swanson, J Anim Sci. 2021 Jan 1;99(1):skab014.
DEMONSTRATION OF SAFETY, TOLERABILITY AND UTILITY OF AMO BIOSIMILARS IN CATS.
Patrícia M Oba, Anne H Lee, Sara Vidal, Romain Wyss, Yong Miao, Yemi Adesokan, Kelly S Swanson, Effect of a novel animal milk oligosaccharide biosimilar on macronutrient digestibility and gastrointestinal tolerance, fecal metabolites, and fecal microbiota of healthy adult cats, Journal of Animal Science, Volume 99, Issue 1, January 2021, skaa399
PRODUCTION OF SCFA & REDUCTION IN UNDESIRABLE MICROBES BY AMO BIOSIMILARS.
Patrícia M Oba, Sara Vidal, Romain Wyss, Yong Miao, Yemi Adesokan, Kelly S Swanson. Effect of a novel animal milk oligosaccharide on the gut microbial communities and metabolites of in vitro incubations using feline and canine fecal inocula. Journal of Animal Science, Volume 98, Issue 9, September 2020, skaa273.